CytoMed Therapeutics Ltd (GDTC) KPIs and segments
Close on Nov 17, 2026Market cap $9.26MP/E –Yield –
KPIs & segments
Operating metrics and segments that drive CytoMed Therapeutics's business
CytoMed Therapeutics's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
| Add to chart | Metric | Q4 2025 | Q4 2024 | Q4 2023 |
|---|---|---|---|---|
Immune cell therapy(S$M) | 5.93 | 9.06 | 12.4 | |
CBU service & related therapy(S$M) | 2.05 | 1.01 | ||
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-03-31.
See a number that looks wrong?